Medical Congress News

Medical Digest & Congress Report

Health EN ↓ 777 episodi

The MedicalDigest.org / CongressReport.eu podcast covers the latest evidence based medical news from cardiology, hematology, oncology, diabetology, pulmonology, dermatology, urology and more. Made for healthcare professionals and researchers, we are an independent, open-access platform. CongressReport.eu portal enables HCPs to get acquainted with new clinical trial results, medical diagnostic and treatment guidelines. Our non-promotional website collects and stores the relevant scientific information, KOL insights, key lectures, poster presentations in a user-friendly format.

Visita il sito del podcast e sostieni chi lo crea: medicaldigest.org

Autore

Medical Congress News

Categoria

Health

Sito del podcast

medicaldigest.org

Ultimo episodio

27 ott 2026

Dove ascoltare?

I podcast nell'app Replaio Radio In arrivo

I podcast stanno per arrivare nell'app. Installala ora e scopri per primo un modo tutto nuovo di vivere i podcast

Scaricala su Google Play Installala gratis Android quasi 10 mln di download · valutazione 4,8 iOS in arrivo

Episodi

Remote BP Monitoring and Drug Titration – Does it work? How do we do it? - report from AHA 2025 03.12.2025

Professor Beverly B. Green shares her insights on remote BP monitoring and drug titrationat after the AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:remote-bp-monitoring-and-drug-titration-does-it-work-how-do-we-do-it

Effectiveness of High-Dose vs. Standard-Dose Inactivated Influenza Vaccine in Individuals with and without Atherosclerotic Cardiovascular Disease: A Pooled FLUNITY-HD Trial Analysis 03.12.2025

Professor Manan Pareek shares his insights on the results from the FLUNITY-HD trial analysis at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:effectiveness-high-dose-vs-standard-dose-inactivated-influenza-vaccine-individuals-and-without-atherosclerotic-cardiovascular-disease-pooled-flunity-hd-trial-analysis

Blood Pressure and Symptomatic Hypotension with Dapagliflozin vs. Placebo in Patients Hospitalized with Heart Failure - report from AHA 2025 03.12.2025

Professor Siddharth M. Patel shares his insights on the results from the DAPA ACT HF-TIMI 68 trial at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:blood-pressure-and-symptomatic-hypotension-dapagliflozin-vs-placebo-patients-hospitalized-heart-failure

DASH-Patterned Groceries Reduce Blood Pressure - report from AHA 2025 03.12.2025

Professor Stephen P. Juraschek discusses the results from the GoFresh randomized clinical trial presented at at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:dash-patterned-groceries-reduce-blood-pressure

TUXEDO-2: Ticagrelor vs. Prasugrel in Patients With Diabetes and Multivessel Disease After PCI - report from AHA 2025 03.12.2025

Professor Sripal Bangalore discusses the findings from the TUXEDO-2 trial presented at at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:tuxedo-2-ticagrelor-vs-prasugrel-patients-diabetes-and-multivessel-disease-after-pci

Aldosterone and Mineralocorticoid Receptors: New Paradigms and Novel Therapies - report from AHA 2025 03.12.2025

Professor John M. Flack shares his insights on the new paradigms and novel therapies in aldosterone and mineralocorticoid receptors at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:aldosterone-and-mineralocorticoid-receptors-new-paradigms-and-novel-therapies

Navigating AHA Scientific Statements: Advancing Evidence-Based Cardiovascular Care - report from AHA 2025 03.12.2025

Professor Bradley S. Marino shares his insights on the advancing evidence-based cardiovascular care at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:navigating-aha-scientific-statements-advancing-evidence-based-cardiovascular-care

A Randomized Clinical Trial Evaluating Vitamin D Normalization on Major Adverse Cardiovascular-Related Events Among Acute Coronary Syndrome Patients: The TARGET-D Trial - report from AHA 2025 02.12.2025

Professor Heidi T. May explains heart attack risk halved in adults with heart disease taking tailored vitamin D doses at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:randomized-clinical-trial-evaluating-vitamin-d-normalization-major-adverse-cardiovascular-related-events-among-acute-coronary-syndrome-patients-target-d-trial

First-in-human trial of CRISPR gene-editing therapy safely lowered cholesterol, triglycerides - report from AHA 2025 02.12.2025

Professor Stephen Nicholls shares his insights on the first-in-human trial of CRISPR gene-editing therapy at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:first-human-trial-crispr-gene-editing-therapy-safely-lowered-cholesterol-triglycerides

Once-weekly Tirzepatide versus Dulaglutide for Heart Failure Outcomes in Patients with Type 2 Diabetes, ASCVD, and History of Heart Failure - report from AHA 2025 02.12.2025

Professor Stephen Nicholls shares his insights on the pre-specified analysis of the SURPASS-CVOT Randomized Clinical Trial at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:once-weekly-tirzepatide-versus-dulaglutide-heart-failure-outcomes-patients-type-2-diabetes-ascvd-and-history-heart-failure

Impact of Cardiovascular-Focused Messaging to Improve Influenza Vaccination on Cardiovascular-Kidney-Metabolic Care Patterns and Clinical Outcomes: Insights from the KP VACCINATE Megatrial 02.12.2025

Professor Ankeet Bhatt shares his insights from the KP VACCINATE Megatrial presented at at AHA Scientific Sessions 2025. Videó: https://medicaldigest.org/scientific-contents/interview:impact-cardiovascular-focused-messaging-improve-influenza-vaccination-cardiovascular-kidney-metabolic-care-patterns-and-clinical-outcomes-insights-kp-vaccinate-megatrial

Resistance Exercise Therapy After COVID-19 Infection: a Randomized, Controlled Trial - report from AHA 2025 02.12.2025

Professor Stuart Gray shares his insights on the resistance exercise therapy after COVID-19 infection at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:resistance-exercise-therapy-after-covid-19-infection-randomized-controlled-trial

Metformin as an Adjunctive Therapy to Catheter Ablation of Atrial Fibrillation - report from AHA 2025 02.12.2025

Professor Amrish Deshmukh shares his insights on metformin as an adjunctive therapy to catheter ablation of atrial fibrillation at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:metformin-adjunctive-therapy-catheter-ablation-atrial-fibrillation

Highlights of AHA / ACC Blood Pressure Management Guideline 02.12.2025

Professor Daniel Jones shares his insights on the AHA / ACC Blood Pressure Management Guideline at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:highlights-aha-acc-blood-pressure-management-guideline

POLY-HF: Daily Polypill Boosts Heart Function, QOL, and Cuts Hospitalizations in Underserved Patients With HFrEF - report from AHA 2025 01.12.2025

Professor Ambarish Pandey presented the data of POLY-HF trial at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:poly-hf-daily-polypill-boosts-heart-function-qol-and-cuts-hospitalizations-underserved-patients-hfref

SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF patients without diabetes - report from AHA 2025 01.12.2025

Professor Juan J. Badimon discusses the SOTA-P-CARDIA Trial, a randomized trial of sotagliflozin in HFpEF patients without diabetes, presented at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:sota-p-cardia-trial-randomized-trial-sotagliflozin-hfpef-patients-without-diabetes

The Clinicians view on the 2025 Guideline for Acute Coronary Syndromes - report from AHA 2025 01.12.2025

Professor Matthew Tomey discusses the clinicians view on the2025 Guideline for Acute Coronary Syndromes at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:clinicians-view-2025-guideline-acute-coronary-syndromes

The New 2025 Guideline for Acute Coronary Syndromes: The European perspective - report from AHA 2025 01.12.2025

Professor Tiziana Claudia Aranzulla shares her insights on the Guideline for Acute Coronary Syndromes from the European perspective at AHA Scientific Sessions 2025. Video: https://medicaldigest.org/scientific-contents/interview:new-2025-guideline-acute-coronary-syndromes-european-perspective

State of the art tumor-targeting IL-12 immunocytokine therapies - report from SITC 2025 27.11.2025

Dr. Gregory Conn shares his insights on state of the art tumor-targeting IL-12 immunocytokine therapies after SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:state-art-tumor-targeting-il-12-immunocytokine-therapies

Reprogramming the Immune Microenvironment to Intercept Lung Adenocarcinoma Precancer - report from SITC 2025 27.11.2025

Professor Jianjun Zhang shares his insights on reprogramming the immune microenvironment to intercept lung adenocarcinoma precancer at SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:reprogramming-immune-microenvironment-intercept-lung-adenocarcinoma-precancer

Primary analysis of patients with high-risk localized, locally recurrent, or regionally advanced cutaneous squamous cell carcinoma treated with neoadjuvant PD-1 therapy - report from SITC 2025 27.11.2025

Professor Gino In presented data from the NeoPOWER trial, to study the role of neoadjuvant PD-1 alone in CSCC at SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:primary-analysis-patients-high-risk-localized-locally-recurrent-or-regionally-advanced-cutaneous-squamous-cell-carcinoma-treated-neoadjuvant-pd-1-therapy

Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma - report from SITC 2025 27.11.2025

Professor William Decker discusses the Phase I Trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma at SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:phase-i-trial-doc1021-cell-based-immunotherapy-resectable-or-borderline-resectable-pancreatic-ductal-adenocarcinoma

How to optimize PD1/PDL1 treatment? - report from SITC 2025 27.11.2025

Professor Gordon J. Freeman shares his insights on how to optimize PD1/PDL1 treatment at SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:how-optimize-pd1pdl1-treatment

Modulating the Tumor Microenvironment with T Cell Bispecifics - report from SITC 2025 27.11.2025

Professor Sumit K. Subudhi shares his insights on modulating the tumor microenvironment with T Cell bispecifics at SITC's 40th Anniversary Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:modulating-tumor-microenvironment-t-cell-bispecifics

Comparative Cardioprotective Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors in Pulmonary Arterial Hypertension: Insights from a Large-Scale Real-World data analysis 27.11.2025

Dr. Saud Alawad and Prof. Sunil Sharma discuss the comparative cardioprotective effects of GLP-1 receptor agonists versus SGLT2 inhibitors in pulmonary arterial hypertension after the American College of Chest Physicians (CHEST) 2025 Annual Meeting. Video: https://medicaldigest.org/scientific-contents/interview:comparative-cardioprotective-effects-glp-1-receptor-agonists-versus-sglt2-inhibitors-pu...

Ascolta il podcast Medical Digest & Congress Report su Replaio

Radio e podcast in un'unica app - gratis e senza registrazione. Installala oggi e non perderti il lancio

Scaricala su Google Play

Replaio non è un editore di podcast; i nomi dei programmi, le copertine e l'audio appartengono ai rispettivi autori e vengono distribuiti tramite feed RSS pubblici